Antibody–drug conjugates (ADCs) are gradually revolutionizing clinical cancer therapy. The antibody–drug conjugate linker molecule determines both the efficacy and the adverse effects, and so has a major infl
抗体偶联药物再战江湖 抗体偶联药物(Antibody–drug conjugates,ADC)是通过特定连接子(linker)将抗体和小分子细胞毒药物连接而成的复合药物。通常情况下,ADCs可以被认为是一种前药,借助抗体对肿瘤细胞表面抗原的特异性识别作用抵达目标细胞,在内吞作用下进入细胞,释放毒素小分子,发挥杀伤作用。也有一些ADC不进行内化,而是...
E.E. Hong, R. Chari, Linker design for antibody-drug conjugates, in: J. Wang, W.C. Shen, J.L. Zaro (Eds.), Antibody-Drug Conjugates, Springer, New York, NY, 2015, pp. 49-78.Hong, E.E.; Chari, R.V.J. Linker design for antibody-drug conjugates. In Antibody-...
ADCs(antibody-drugconjugates)技术是通过linker将单抗和药物分子偶联在一起,利用抗体的特异性靶向运输药物分子到靶组织发挥作用,降低药物的系统性毒副作用,提高药物治疗窗和拓展抗体治疗潜能[1]。血液中循环的ADC与靶抗原结合后,通过网格蛋白介导的内吞作用被内化(图1)[2]。内化的复合物随后进入内体-溶酶体途径,大多...
Antibody-drug conjugates (ADCs) are one of fastest growing classes of oncology drugs in modern drug development. By harnessing the powers of both cytotoxic chemotherapy and targeted therapy, ADCs are unique in offering the potential to deliver highly pot
ADC Linker: SPDP SPDP(SPDP Crosslinker) 是一种谷胱甘肽可切割的连接桥,用于抗体-药物结合物(ADC)。 MC-Val-Cit-PAB是可被组织蛋白酶切割的 ADC 连接桥,用于制备抗体-药物偶联物。 Drug-Linker Conjugates for ADC: SMCC-DM1 SMCC-DM1 (...
Antibody–drug conjugates (ADCs) are an emerging class of targeted therapeutics developed predominately for the treatment of cancer. Comprising a tumour-targeting monoclonal antibody with a payload attached via chemical linker (Fig.1), ADCs enable the selective delivery of highly cytotoxic payloads to...
ADC Linker: SPDP SPDP(SPDP Crosslinker) 是一种谷胱甘肽可切割的连接桥,用于抗体-药物结合物(ADC)。 MC-Val-Cit-PAB是可被组织蛋白酶切割的 ADC 连接桥,用于制备抗体-药物偶联物。 Drug-Linker Conjugates for ADC: SMCC-DM1 SMCC-DM1 (DM1-SMCC)是由连接桥 SMCC 和 毒性分子 DM1 连接而成的,可用来制备...
简单解释一下:抗体与中间linker通过酰胺交换反应连接,中间linker与linker-drug通过点击化学反应或生物正交反应连接,linker-drug中linker与drug也同样通过点击化学反应或生物正交反应连接。由于中间linker可以具有不同接头,linker-drug也可以携带不同载荷的药物,因此作者便可以合成不同载药量的单药或多药ADC。至此,作者合成了...
1月8日,Araris宣布与罗氏子公司Chugai Pharmaceutical达成合作,双方将基于Araris旗下linker-conjugation技术平台AraLinQ,针对未公开的靶点开发下一代ADC,该交易总金额为7.8亿美元。在同一时间段,百奥赛图与育世博宣布达成合作,双方将基于百奥赛图的RenLite平台与育世博的抗体双药物连接(AD2C)技术,开发双特异性抗体双药...